Gpr139 - G protein-coupled receptor 139 Gene
Species: Rattus norvegicus
About Gpr139
This gene has 1 transcript (splice variant), 335 orthologues and 1 paralogue. Restricted expression toward (RPKM 8.4).
Summary
Predicted to enable identical protein binding activity and neuropeptide receptor activity. Predicted to be involved in neuropeptide signaling pathway. Predicted to act upstream of or within Phospholipase C-activating G protein-coupled receptor signaling pathway. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. Orthologous to human GPR139 (G protein-coupled receptor 139). [provided by Alliance of Genome Resources, Apr 2022]
Gpr139 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001024241.2 | NP_001019412.1 | probable G-protein coupled receptor 139 |
Gpr139 Protein Structure
7tmA_GPR139: cd15919 (18 - 287)
7tmA_GPR139: cd15919 (19 - 45)
7tmA_GPR139: cd15919 (53 - 78)
7tmA_GPR139: cd15919 (92 - 122)
7tmA_GPR139: cd15919 (134 - 154)
7tmA_GPR139: cd15919 (171 - 196)
7tmA_GPR139: cd15919 (212 - 244)
7tmA_GPR139: cd15919 (255 - 280)
- 0
- 100
- 200
- 300
- 345 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
probable G-protein coupled receptor 139 |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-132228 | Zelatriazin | Agonist | 99.88% | Phase 2 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-19838 | JNJ-63533054 | Agonist | 99.80% | Unkown |
| HY-128057 | NCRW0005-F05 | Antagonist | 99.94% | Unkown |
| HY-119168 | LP-471756 | Antagonist | 99.53% | Unkown |
| HY-101777 | TC-O 9311 | Agonist | 99.83% | Unkown |
| HY-149651 | GPR139 agonist-2 | Agonist | 99.85% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service